NASDAQ:VRTX Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis $547.03 -0.86 (-0.16%) Closing price 04:00 PM EasternExtended Trading$546.33 -0.70 (-0.13%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vertex Pharmaceuticals Stock (NASDAQ:VRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vertex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$535.46▼$548.6750-Day Range$485.22▼$558.8852-Week Range$412.27▼$568.67Volume1.08 million shsAverage Volume1.40 million shsMarket Capitalization$138.69 billionP/E Ratio35.20Dividend YieldN/APrice Target$596.44Consensus RatingModerate Buy Company Overview Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia. Vertex serves patients in the United States and international markets, including Europe. Reshma Kewalramani has served as the company’s president and chief executive officer since 2020.AI Generated. May Contain Errors. Read More Vertex Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreVRTX MarketRank™: 3.400759361085 of 5 starsVertex Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 396th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingVertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 25 buy ratings, 2 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Vertex Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vertex Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth11.30% Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 11.30% in the coming year, from $16.10 to $17.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 35.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 35.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.31.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 2.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 6.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.90% of the float of Vertex Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVertex Pharmaceuticals has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vertex Pharmaceuticals has recently increased by 12.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.72 News SentimentVertex Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Vertex Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 10 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows31 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.20% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vertex Pharmaceuticals' insider trading history. Receive VRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRTX Stock News HeadlinesBioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?2 hours ago | fool.comiShares Biotechnology ETF (IBB) Adds Gilead and Amgen on Nov. 9November 11 at 7:26 AM | finance.yahoo.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 11 at 1:00 AM | Profits Run (Ad)Missed Vertex Pharmaceuticals' Run? What Holders Had To BelieveNovember 8 at 6:56 PM | finance.yahoo.comVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Rated "Moderate Buy" by Sell-Side AnalystsNovember 7, 2026 | americanbankingnews.comVertex Pharmaceuticals: Costs Now Outgrow Sales, And The Price Needs A Second VertexNovember 6, 2026 | seekingalpha.comVertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Barclays Analyst SaysNovember 6, 2026 | americanbankingnews.comMaxim Group Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)November 5, 2026 | theglobeandmail.comSee More Headlines VRTX Stock Analysis - Frequently Asked Questions How have VRTX shares performed this year? Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of 2026. Since then, VRTX shares have increased by 20.6% and is now trading at $546.5660. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) issued its quarterly earnings results on Monday, November, 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts' consensus estimates of $4.82 by $0.06. The business's revenue was up 11.8% on a year-over-year basis. Read the conference call transcript. Does Vertex Pharmaceuticals have any subsidiaries? Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others. Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' top institutional shareholders include Pictet Asset Management Holding SA (0.25%), Sumitomo Mitsui Trust Group Inc. (0.23%), Aberdeen Group plc (0.21%) and Voya Investment Management LLC (0.18%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose and Sangeeta N Bhatia. View institutional ownership trends. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Salesforce (CRM), Micron Technology (MU), Alibaba Group (BABA) and Netflix (NFLX). Company Calendar Last Earnings11/02/2026Today11/11/2026UBS Global Biopharma Conference 202611/16/2026Jefferies Global Healthcare Conference11/17/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 4 weeks, VRTX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VRTX CIK875320 Webwww.vrtx.com Phone(617) 341-6100Fax617-576-2109Employees6,400Year Founded1989Price Target and Rating Average Price Target for Vertex Pharmaceuticals$596.44 High Price Target$725.00 Low Price Target$442.00 Potential Upside/Downside+9.0%Consensus RatingModerate Buy Rating Score (0-4)2.96 Research Coverage28 Analysts Profitability EPS (Trailing Twelve Months)$15.54 Trailing P/E Ratio35.20 Forward P/E Ratio30.53 P/E Growth2.92Net Income$3.95 billion Net Margins30.70% Pretax Margin36.74% Return on Equity21.98% Return on Assets15.50% Debt Debt-to-Equity Ratio0.17 Current Ratio2.34 Quick Ratio1.89 Sales & Book Value Annual Sales$12.00 billion Price / Sales11.56 Cash Flow$17.45 per share Price / Cash Flow31.34 Book Value$82.46 per share Price / Book6.63Miscellaneous Outstanding Shares253,540,000Free Float253,031,000Market Cap$138.69 billion OptionableOptionable Beta0.28 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:VRTX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
